Home › Posts tagged Epidermal Growth Factor Receptor (EGFR)
Blog Archives

The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

June 30, 2017 – The below citation from PubMed addresses an vey important issue associated with genetic testing in theragenomic and personalized medicine. It is the question if the genetic test used to stage, classify, or determine treatability of a disease with a given drug is accurate.

…

Read more ›

Tags: , , , , , , , ,

This is it: First blood test to detect EGFR gene mutations in NSCLC

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, Thasso Post, Theragenomic Medicine 1 Comment ↓

June 03, 2016 – This is a huge step in the application of theragenomic medicine in cancer patients in the quest to deliver highly individualized health care for patients. Thus, on June 01, the American Food & Drug Administration (FDA) approved the cobas EGFR Mutation Test v2,

…

Read more ›

Tags: , , , , , , , , , , ,

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine, Uncategorized No Comments ↓

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.

…

Read more ›

Tags: , , , , , , ,

Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC)

Posted on by by Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

…

Read more ›

Tags: , , , , , , ,

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

Posted on by by Posted in Genetic Predisposition, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

…

Read more ›

Tags: , , , , , , ,

FDA Approves Companion Genetic Diagnostic Test for Erlotinib [Tarceva] in NSCLC

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Thasso Post No Comments ↓

May 14, 2013 – The US Food and Drug Administration (FDA) today announced the approval of the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor (EGFR) gene mutations,

…

Read more ›

Tags: , , , , , , , , , ,

thasso: donate

thasso: conditions

thasso: newest tweets

 

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

RSS random genetics

  • Genetic tests may differ in their interpretation of certain variants July 1, 2020
    (HealthDay)—Different genetic test interpretations have been identified for genetic variants, and some of these can impact patient management, according to a research letter published online June 30 in the Annals of Internal Medicine.
  • How does our brain fold? Study reveals new genetic insights July 1, 2020
    New research is helping unlock the mystery of how the brain folds as a baby develops in the womb—a process critical to healthy brain function.
  • New infectious disease test accurately diagnoses infection in minutes July 1, 2020
    Melbourne researchers have developed a fast, new test for infections and infectious diseases that could transform Australia's ability to provide targeted clinical care and respond to pandemics and biosecurity threats.
  • Next-generation sequencing to provide precision medicine for rare metabolic disorders June 30, 2020
    An international team of scientists from Switzerland Spain, has studied the genetic basis of aromatase deficiency, a rare metabolic disorder that prevents the production of estrogens in humans, according to new research in JCEM (Journal of Clinical Endocrinology and Metabolism). The latest studies on aromatase deficiency in humans come from the group of Amit V. […]
  • New genomic atlas of the developing human brain June 30, 2020
    For the nascent brain of a human embryo to develop into the complex organ that controls human consciousness, a finely tuned sequence of genetic events has to take place; hundreds of genes are activated and deactivated in a precise symphony. Mutations in these genes disrupt the molecular instruments of the symphony and, if they occur […]

RSS random science

  • Understanding molecular mechanisms of air pollution's impact on ILD critical July 1, 2020
    More research must be done to investigate the role of air pollution on the epigenome in patients with interstitial lung diseases (ILDs), in order to develop strategies that minimize the effects of these pollutants, according to a new article published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
  • Researchers develop computational model to build better capacitors July 1, 2020
    Researchers have developed a computational model that helps users understand how changes in the nanostructure of materials affect their conductivity - with the goal of informing the development of new energy storage devices for a wide range of electronics.
  • Traffic data show drastic changes in Floridians' behavior at onset of the pandemic July 1, 2020
    Using same-day traffic volumes for March 2019 and March 2020 across Florida, researchers examined the relationship of key governmental requests for public isolation and travel limitations. Results show the drastic changes in human behavior during the onset of the pandemic. Traffic volumes by March 22, 2020, dropped by 47.5% compared to that same point in […]
  • A shake-up in cell culturing: Flame sterilization may affect the culture July 1, 2020
    Researchers from the University of Tsukuba have found that flame-sterilizing shake-flasks, to avoid introducing microbial contaminants, considerably increases the carbon dioxide concentration in the flasks. This enhanced carbon dioxide concentration affects the growth of some microbial species, which may affect the quantity of vaccines or other valuable substances produced by the microbes.
  • Lifetime discrimination may increase risk of hypertension among African Americans July 1, 2020
    A study of African Americans in Mississippi shows an association between experiencing discrimination over a lifetime and developing hypertension (also referred to as high blood pressure).African Americans who reported medium and high levels of lifetime discrimination, compared to those who reported low lifetime discrimination, had a higher risk for hypertension.
Top